TEL: 031 920 0037E-Mail: [email protected]
홈페이지: ncc.re.kr/symposium/ 평점: 대한의사협회 6평점
The 12th NCC International Symposium
Korea
Japan
Italy
USA
Netherlands
China
Taiwan
International Conference Hall, National Cancer Center KoreaJune 15, 2018
Rare cancers : are you ready to keep an eye on?
주최 국립암센터 문의 교육훈련팀
The advances in radiation oncology: proton therapy for chordomas
15:40-15:50 Coffee break
사전등록연자프로필
08:30-09:00
09:00-09:10
09:10-09:30
09:30-10:10
10:10-10:20
10:20-11:00
11:00-11:40
11:40-13:00
13:00-13:40
13:40-14:20
14:20-14:30
14:30-15:20
15:20-15:40
15:50-16:30
16:30-17:10
17:10-17:30
17:30-17:40
Registration
Opening address and welcome remarks
Burden of rare cancers in Korea
Network and research on rare cancers in Japan
Coffee break
Network and research on rare cancers in European Union
Precision oncology based on tumor evolution and gene-drug map
Lunch
Development of targeted new agents for children with cancer
Clinically actionable novel targets in rare cancers
Coffee break
Sarcoma research toward novel clinical application
Closing remarks
Session 01 Disease burden & network
Session 02
Session 03
Registration and Opening
Challenges to tackle
Beyond the frontline
Gabe Sonke (Netherlands Cancer Institute, Netherlands)
Sang Yoon Park (National Cancer Center, Korea)
(NCC Graduate School of Cancer Science and Policy, Korea)Jong Bae Park
and tumor microenvironment Molecular interplay between glioblastoma stem cell
Tadashi Kondo (National Cancer Center, Japan)
Yu Wang (The General Hospital of PLA, China)
Kwan Ho Cho (National Cancer Center, Korea)
Chueh-Chuan Yen
Eun Sook Lee (President, National Cancer Center, Korea)
Young Joo Won (National Cancer Center, Korea)
Tomohiro Matsuda (National Cancer Center, Japan)
Lisa Francesca Licitra (Istituto Nazionale Tumori in Milan, Italy)
Do-Hyun Nam (Samsung Medical Center, Korea)
Byoung Gie Kim (Samsung Medical Center, Korea)
Yeul-Hong Kim (Korea University Anam Hospital, Korea)
Sang Jae Park (National Cancer Center, Korea)
Byung Kiu Park (National Cancer Center, Korea)
(The Children's Hospital of Philadelphia, USA)Peter C. Adamson
(Taipei Veterans General Hospital, Taiwan)
based upon cancer immunology and available techniques
Personalized and combinational cancer immunotherapy
HIPEC following primary vs. Interval cytoreductive surgery in ovarian cancer
Hyperthermic intraperitoneal chemotherapy in ovarian cancer
[Joint Talk]
INVITED SPEAKERSINVITED SPEAKERS
Session 01 Disease burden & network
Session 03 Beyond the frontline
Burden of rare cancers in Korea
Young Joo Won
HeadDivision of Cancer Registration&Surveillance, National Cancer Control Institute(National Cancer Center, Korea)
Chair, Children’s Oncology Group(The Children's Hospital of Philadelphia, USA)
Chief and professorCenter for Immuno-oncology, Department of Oncology(Taipei Veterans General Hospital, Taiwan)
Section HeadNational Cancer Registry Section,Center for Cancer Registries(National Cancer Center, Japan)
Medical oncologist(Netherlands Cancer Institute, Netherlands)
Senior ScientistCenter for Uterine Cancer(National Cancer Center, Korea)
Deputy DirectorLaboratory of Oncology(The General Hospital of PLA, China)
ChiefDivision of Rare Cancer Research(National Cancer Center, Japan)
Dean(NCC Graduate School of Cancer Science and Policy, Korea)
Senior ScientistProton Therapy Center(National Cancer Center, Korea)
DirectorHead and Neck Cancer Medical Oncology Department(Istituto Nazionale Tumori in Milan, Italy)
Professor, Dept. of NeurosurgeryDirector, Institute for Refractory Cancer Research(Samsung Medical Center, Korea)
Tomohiro Matsuda
Lisa Francesca Licitra
Do-Hyun Nam
Yu Wang
Tadashi Kondo
Kwan Ho Cho
Jong Bae Park
Peter C. Adamson
Chueh-Chuan Yen
Gabe Sonke
Sang Yoon Park
Development of targeted newagents for children with cancer
Clinically actionable novel targets in rare cancers
Network and research onrare cancers in Japan
Hyperthermic intraperitoneal chemotherapy in ovarian cancer
Network and research on rare cancers in European Union
HIPEC following primary vs. Interval cytoreductive surgery in ovarian cancer
Precision oncology based on tumor evolution and gene-drug map
The advances in radiation oncology: proton therapy for chordomas
Molecular interplay between glioblastoma stem cell and tumor microenvironment
Sarcoma research toward novel clinical application
Personalized and combinational cancer immunotherapy based upon cancer immunology and available techniques
Session 02 Challenges to tackle
The 12th NCC International Symposium
